Arrowhead Research | ARWR - Gross Profit On Sales


Arrowhead Research reported $256.47M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Incyte USD 1.39B 118.68M Dec/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
Merck USD 13.42B 431M Sep/2025
Moderna USD 226M 583M Dec/2025
Nektar Therapeutics USD 13.75M 650K Jun/2024
Novartis USD 10.25B 570M Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
TG Therapeutics USD 154.43M 20.81M Dec/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025
Xencor USD 21M 22.61M Sep/2025